Abliva AB
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic … Read more
Market Cap & Net Worth: Abliva AB (ABLI)
Abliva AB (ST:ABLI) has a market capitalization of $63.80 Million (Skr715.67 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #21577 globally and #239 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Abliva AB's stock price Skr0.44 by its total outstanding shares 1611879936 (1.61 Billion).
Abliva AB Market Cap History: 2015 to 2025
Abliva AB's market capitalization history from 2015 to 2025. Data shows change from $1.38 Billion to $63.80 Million (-30.63% CAGR).
Abliva AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Abliva AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
257.48x
Abliva AB's market cap is 257.48 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.38 Billion | $2.50 Million | -$90.12 Million | 551.31x | N/A |
| 2016 | $478.47 Million | $14.00K | -$70.24 Million | 34176.53x | N/A |
| 2017 | $428.18 Million | $27.00K | -$66.73 Million | 15858.58x | N/A |
| 2018 | $198.29 Million | $5.00K | -$68.37 Million | 39657.09x | N/A |
| 2019 | $192.54 Million | $134.00K | -$76.87 Million | 1436.85x | N/A |
| 2020 | $109.92 Million | $216.00K | -$59.88 Million | 508.88x | N/A |
| 2021 | $85.85 Million | $151.00K | -$123.50 Million | 568.56x | N/A |
| 2022 | $25.72 Million | $31.00K | -$84.96 Million | 829.67x | N/A |
| 2023 | $35.27 Million | $137.00K | -$95.51 Million | 257.48x | N/A |
Competitor Companies of ABLI by Market Capitalization
Companies near Abliva AB in the global market cap rankings as of March 19, 2026.
Key companies related to Abliva AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Abliva AB Historical Marketcap From 2015 to 2025
Between 2015 and today, Abliva AB's market cap moved from $1.38 Billion to $ 63.80 Million, with a yearly change of -30.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr63.80 Million | +5.21% |
| 2024 | Skr60.64 Million | +71.89% |
| 2023 | Skr35.27 Million | +37.15% |
| 2022 | Skr25.72 Million | -70.04% |
| 2021 | Skr85.85 Million | -21.90% |
| 2020 | Skr109.92 Million | -42.91% |
| 2019 | Skr192.54 Million | -2.90% |
| 2018 | Skr198.29 Million | -53.69% |
| 2017 | Skr428.18 Million | -10.51% |
| 2016 | Skr478.47 Million | -65.31% |
| 2015 | Skr1.38 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 16th, 2026 the market cap of Abliva AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $63.80 Million USD |
| MoneyControl | $63.80 Million USD |
| MarketWatch | $63.80 Million USD |
| marketcap.company | $63.80 Million USD |
| Reuters | $63.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.